Sales Growth of ZUNVEYL
The third quarter of 2025 saw a significant increase in sales for ZUNVEYL, with ex-factory purchases rising 44% quarter-over-quarter and demand sales bottles dispensed growing by 102% from Q2.
Successful Engagement in Long-Term Care Market
Alpha Cognition engaged 2,038 homes in Q3, bringing the total reach to 2,942 unique homes, with 70% of those homes placing repeat orders.
Positive Clinical Feedback
ZUNVEYL has shown good clinical performance with reports of cognition improvement and limited adverse events, maintaining a low single-digit rate of GI adverse events.
Strong Financial Position
The company raised $38 million in net proceeds through an equity offering, extending their operational runway into 2027.
Progress in Research and Development
Alpha Cognition plans to initiate two studies, CONVERGE and BEACON, to assess ZUNVEYL's cognitive benefits and tolerability, with completion expected in late 2026.